Covid-19 Vaccine: Aurobindo Expects Phase-I, II Trials By End Of 2020
Aurobindo Pharma has said it is expecting its proposed vaccine candidate for Covid-19 to undergo phase-1 and 2 trials by the end of 2020, while Phase III may be undertaken during March-April next year.
Managing Director Narayanan Govindarajan in the recently held earnings call with analysts said the city-based pharma major had earmarked $150-200 million towards capital expenditure during the current fiscal year.
He said the vaccine for Covid-19 was being developed by Profectus BioSciences in the US, which was acquired by Aurobindo Pharma’s subsidiary Auro Vaccines LLC.
According to Govindarajan, the company's viral vaccine manufacturing capacity in India would be undertaken in two phases.
Titi Coles Legacy In Finance: Pioneering Diversity And Leadership
Titi Cole, one of the most senior Black women in the world of finance, recently exited her high-profile role at Citi. He... Read more
Rising Rates, Rising Challenges: Bankers Adapt To Serve Troubled Companies In A Changing Economic Landscape
As interest rates climb, troubled companies are facing heightened financial pressures, prompting them to seek assistance... Read more
The Elusive Nature Of Fraud Detection: Exploring The Auditor's Dilemma
In the intricate world of financial reporting, auditors serve as guardians of integrity, tasked with uncovering discrepa... Read more
The Battle For Depositors: US Lenders Ramp Up Efforts Amidst Rate Uncertainty
In the competitive landscape of the US banking sector, retaining depositors is paramount for lenders seeking to maintain... Read more
Beyond Capital: Unveiling The Complexities Of Bank Failure Prediction
In the realm of banking, the ability to predict and prevent failures is paramount for financial stability and consumer c... Read more
Central Banks And The Economic Horizon: Steering Through Uncertaintie
In the evolving landscape of global financial markets, the strategic role of central banks has come under intense scruti... Read more